Alli first centralized switch
This article was originally published in The Tan Sheet
Executive Summary
The European Union approves GlaxoSmithKline's weight-loss drug alli (orlistat 60 mg) for nonprescription sale in all 27 member states and Norway. The company says Jan. 21 it plans to launch alli - the first centralized EU switch - in the coming months. While all EU members agree to sell alli as nonprescription, each country chooses whether to make it available over the counter or behind the counter, the European Medicines Agency says (1"The Tan Sheet" Nov. 17, 2008, p. 6)